Protein-losing enteropathy after the Fontan operation  by Feldt, Robert H. et al.
PROTEIN-LOSING ENTEROPATHY AFTER THE FONTAN OPERATION 
Robert H. Feldt, MD a 
David J. Driscoll, MD a 
Kenneth P. Offord, MS b 
Ruth H. Cha, MS b 
Jean Perrault, MD ° 
Hartzell V. Schaff, MD d 
Francisco J. Puga, MD d 
Gordon K. Danielson, MD d 
Patients were observed after the Fontan operation to determine the 
frequency and severity of protein-losing enteropathy. A total of 427 patients 
who survived for 30 days after the Fontan operation, performed between 
1973 and January 1987, were analyzed and, thus far, proteinllosing 
enteropathy has developed in 47 of 427. The cumulative risk for the 
development of protein-losing enteropathy by 10 years was 13.4% among 
30-day survivors, and 5-year survival after the diagnosis was 46%. Hemo- 
dynamic studies done coincident with the diagnosis of protein-losing 
enteropathy have shown increased systemic venous pressure, decreased 
cardiac index, increased pulmonary vascular resistance, and increased 
ventricular end-diastolic pressure. Medical management of protein-losing 
enteropathy was only partially successful. Statistical analysis has shown 
that factors related to protein-losing enteropathy were ventricular anat- 
omy, increased preoperative ventricular end-diastolic pressure, longer 
operative bypass time, increased length of hospital stay, and postoperative 
renal failure. This study suggests that scrupulous selection of cases for the 
Fontan operation is mandatory and that certain perioperative factors may 
predispose to this serious complication of the Fontan procedure. (J Thorac 
Cardiovasc Surg 1996;112:672-80) 
p rotein-losing enteropathy (PLE) associated with 
cardiovascular disease was first noted in patients 
in whom constrictive pericarditis developed 1 or 
those who had long-standing congestive heart fail- 
ure. 2 PLE also has been reported in patients who 
have had the Mustard procedure for complete trans- 
position of the great arteries and in whom obstruc- 
tion of the intraatrial baffle had developed) It has 
been theorized that PLE results from increased 
systemic venous pressure that subsequently causes 
lymphangiectasis, which has been documented by 
jejunal biopsy. PLE associated with the Fontan 
operation was reported in 1980 and again in 1984. 4, s 
A preliminary review of the experience at the Mayo 
Clinic was reported and the frequency of PLE after 
the Fontan operation was approximately 10%. For 
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another ecent series 6 a 24% frequency of PLE was 
reported after the Fontan operation. 
The purpose of this study was to estimate the 
probability of PLE developing among 30-day survi- 
vors of the Fontan operation. In addition, the clin- 
ical course of patients with PLE was analyzed to 
determine survivability and to describe the effects of 
different options for management. Various preoper- 
ative and perioperative risk factors for the develop- 
ment of PLE were also assessed. An understanding 
of the occurrence and severity of this important 
complication of the Fontan operation, as well as a 
knowledge of certain risk factors that may be asso- 
ciated with PLE, can enhance the ability to select 
optimal candidates for the Fontan operation. 
Methods 
This report is based on patients who had the Fontan 
operation between 1973 and January 1987 at the Mayo 
Clinic and who were alive 30 days after the operation. A
database for these patients has been used for previous 
publications. 71° This database was updated by data from 
recent return visits, reports from local physicians, and 
information obtained from recent written questionnaires 
or telephone interviews. Recent follow-up information 
was available for all 30-day survivors except for five patients 
who were known to be alive 3 to 5 years after their Fontan 
operation. Excluded were patients whose Fontan repair was 
taken down in the first 30 days after the operation. 
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Fig. 1. Survival curve for 427 30-day survivors of the Fontan operation. Time zero is 30 days after the 
operation. 
Current data included vital status, cardiovascular symp- 
toms or signs, medications and other management regi- 
mens, date of onset of PLE if present, clinical course, and 
results of pertinent echocardiographic or hemodynamic 
studies. PLE was considered present when increased 
enteric loss of ch-antitrypsin was documented or the 
clinical syndrome of PLE was present (persistent or 
intermittent edema with hypoproteinemia without evi- 
dence for deficient protein production or excessive pro- 
tein loss from organ systems other than the gastrointesti- 
nal tract). 
To identify factors associated with development of 
PLE, we analyzed several preoperative, perioperative, and 
postoperative factors. Preoperative factors included cal- 
endar year of operation, age at operation, type of ana- 
tomic defect, ventricular anatomy, presence of preopera- 
tive arrhythmia, estimate of ventricular systolic function 
by echocardiographic or angiographic methods, measured 
ventricular end-diastolic pressure, total pulmonary resis- 
tance, and pulmonary arteriolar resistance. Perioperative 
and postoperative factors analyzed included length of 
cardiopulmonary b pass, need for atrioventricular valve 
surgery at the time of the Fontan operation, need for early 
reoperation for any reason, right and left atrial pressures 
at the end of the operation, postoperative arrhythmias, 
postoperative r nal failure, and length of stay in the 
hospital after the operation. For survival analysis, time 
zero was the thirtieth postoperative day, whether or not 
the patient was still hospitalized. 
These factors were analyzed among all 30-day survivors. 
In addition, we assessed survival subsequent tothe devel- 
opment of PLE by standard univariate and multivariate 
analyses previously described by Driscoll and associates. 1° 
Two-tailed p values -< 0.05 were taken as evidence of 
findings not attributable to chance. 
Results 
A total of 427 patients were identified as eligible 
30-day survivors. These included 260 male and 167 
female patients. Basic cardiac anatomic types were 
distributed as follows: tricuspid atresia, 148 patients; 
univentricular heart, 138; and other complex cya- 
notic lesions, 141. The survival curve for all 30-day 
survivors shows that the 10-year survival of these 
patients was 77% (Fig. 1). 
Forty-seven of the 427 patients had sufficient data 
to fulfill the diagnostic criteria for PLE, for a 
cumulative risk at 10 years of 13.4%. The onset of 
PLE after the Fontan operation ranged from 2 
months to 9 years (mean 3.7 years). In 14 of these 47 
patients (30%), PLE developed more than 5 years 
after the Fontan operation. The onset of PLE was 
associated with the development of fluid accumula- 
tion such as pleural effusion, ascites, or peripheral 
edema. Often no recognizable gastrointestinal 
symptoms were present. Only two of 47 patients 
reported significant change in frequency of bowel 
movements. A significant growth delay was noted in 
three patients, and the onset of puberty was consid- 
ered to have been delayed in one patient. 
Current status of patients with PLE. The 5-year 
survival after diagnosis of PLE was 46% (Fig. 2). 
Survivorship was not related to length of time 
between operation and onset of PLE. Among the 20 
current survivors, four patients are in remission. 
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Fig. 2. Survival curve after diagnosis of PLE in patients who have had the Fontan operation. 
Table I. Postoperative hemodynamic f ndings for 
patients with PLE 
Variable No. Mean Range 
Mean right atrial pressure 45 18.2 8-30 
(mm Ug) 
Mean pulmonary artery 41 18.7 8-41 
pressure (ram Hg) 
Cardiac index (L/rain per 29 2.3 1.4-3.7 
square meter) 
Ejection fraction (%) 18 53.2 16-69 
Total pulmonary 31 4.5 0.8-9.9 
resistance (txm 2) 
Pulmonary arteriolar 27 1.8 0.4-5.6 
resistance 0xm 2) 
Ventricular end-diastolic 42 14.8 5-32 
pressure (ram Hg) 
Mean wedge pressure 7 11 3-17 
(mm Hg) 
One patient had transient PLE coincident with a 
Salmonella intestinal infection. Another has been in 
remission for 3 years after cardiac transplantation. 
One patient is currently in remission coincident with 
the placement of a sequential atrioventricular pace- 
maker for intermittent bradycardia. Another patient 
currently is in remission after having had PLE from 
1979 until 1991. This patient derived significant 
clinical benefit after moving from high altitude 
(Denver) to sea level (San Diego). 
Four current survivors have mild PLE that is 
reasonably well controlled by standard anticonges- 
tive measures. These patients remain active and are 
able to take part in normal day-to-day activities. 
Their exercise intolerance is considered mild to 
moderate. Eight patients have PLE and are on 
anticongestive therapy regimens and require peri- 
odic albumin infusions. These patients have definite 
exercise intolerance (New York Heart Association 
class II). Four others currently have severe PLE 
coincident with significant disability (New York 
Heart Association class III). Two are awaiting car- 
diac transplantation and two others have refused 
that option. 
Laboratory data from current PLE survivors in- 
cludes total serum protein values ranging from 3.0 
to 5.9 gm/dl (mean 4.3 gm/dl) and serum albumin 
values ranging from 1.3 to 4.0 gm/dl (mean 2.6 
gm/dl). Serum calcium values range from 4.5 to 9.5 
mg/dl. The patient with the lowest calcium value 
manifested tetany. Six patients had 24-hour al- 
antitrypsin clearances ranging from 46.4 to 584.0 
ml/day (mean 265 ml/day). Normal clearance has 
been determined to be less than 27 ml/day. Lympho- 
cytopenia is common (range 2% to 46% lympho- 
cytes, with a mean of 15% lymphocytes in the 
peripheral smear). 
Hemodynamie findings. In an effort to better 
understand the hemodynamic derangement associ- 
ated with PLE, we tabulated the results of cardiac 
catheterization or echocardiographic studies (or 
both) (Table I). Included were data from postoper- 
ative studies coincident with the development of 
PLE, irrespective of current vital status. The factors 
measured show wide ranges of variability, with the 
tendency for increased right-sided filling pressures, 
decreased cardiac index, increased pulmonary resis- 
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tance, and increased ventricular end-diastolic pres- 
sure. Estimated ventricular ejection fractions were 
decreased (mean 53%). Patients underwent cardiac 
catheterization during hospitalization for treatment 
of edema, fluid accumulation, and congestive heart 
failure. They were considered to be in reasonably 
stable cardiopulmonary states at the time of their 
catheterization. 
Clinical management strategies. For those pa- 
tients who are in remission, treatment has not been 
continued. Of those with PLE who survive, 17 of 20 
(85%) are on regimens that include sodium restric- 
tion. Dietary modification, as has been advocated 
for the treatment in children with intestinal ym- 
phangiectasia from other causes, 11' 12 has been tried 
on four patients but none continued these dietary 
measures on a long-term basis. 
Nineteen of 20 survivors of PLE (95%) are re- 
ceiving digoxin and diuretics. Although the reinsti- 
tution of these anticongestive measures had a sig- 
nificant clinical effect and often was associated with 
a dramatic decrease in enteric protein loss, the 
patients continue to have PLE. Twelve of 20 pa- 
tients (60%) are being treated with afterload-reduc- 
ing agents in their regimen, with similar partial 
benefit. 
Nine of 20 patients (45%) have required periodic 
albumin infusion that is often given before intrave- 
nous administration of furosemide therapy. For the 
patient with marked edema and hypoproteinemia, 
the benefits can be dramatic. The duration of benefit 
is variable and not predictable. Three patients have 
had courses of corticosteroid therapy given in ther- 
apeutic doses for adequate trial periods. None of 
these patients derived any benefit from such ther- 
apy. 
Death and PLE. Of the 96 30-day survivors who 
have subsequently died during follow-up, 27 (28%) 
were patients in whom PLE had developed. Reop- 
eration during follow-up for whatever eason is 
associated with high perioperative mortality among 
patients with PLE. Nine of 12 patients with PLE 
died in connection with their reoperation. Two of 
the deaths at reoperation occurred in patients un- 
dergoing transplantation. These two patients were 
believed to have long-standing congestive heart fail- 
ure and had marked nutritional debilitation. All 
other deaths were attributed to deteriorating ven- 
tricular function and congestive heart failure. 
Univariate analysis of factors associated with 
development of PLE. Factors not associated with 
development of PLE included calendar year of the 
Fontan procedure, sex of the patient, preoperative 
ejection fraction (echocardiography or angiogra- 
phy), presence of preoperative arrhythmia, preoper- 
ative mean pulmonary artery pressure, and preop- 
erative total pulmonary resistance or pulmonary 
arteriolar esistance (Table II). Factors associated 
with development of PLE included ventricular anat- 
omy other than dominant left ventricle and in- 
creased preoperative ventricular end-diastolic pres- 
sure. Patients with tricuspid atresia were less likely 
to have PLE develop than patients with other types 
of defects (Table II). 
Perioperative factors associated with develop- 
ment of PLE (Table II) included longer cardiopul- 
monary bypass time, increased left atrial pressure 
after the operation, longer length of hospital stay, 
and presence of postoperative r nal failure. Postop- 
erative renal failure was considered present when 
the patient needed renal or peritoneal dialysis. Early 
reoperation for any reason was also associated with 
later development of PLE. 
From analysis of continuous variables (Pc in 
Table II), higher total pulmonary resistance, higher 
preoperative ventricular end-diastolic pressure, 
higher mean left atrial pressure after the Fontan 
operation, longer cardiopulmonary b pass time, and 
longer hospital stay were associated with the devel- 
opment of PLE. 
Multivariate analysis. From Cox proportional- 
hazards modeling, the sole preoperative variable 
associated with later development of PLE was 
ventricular anatomy other than dominant left 
ventricle (Prn in Table II). Of perioperative vari- 
ables similarly analyzed, length of hospital stay 
also predicted PLE development. The most sig- 
nificant factor predictive of PLE was the presence 
of renal failure in the postoperative period. PLE 
ultimately developed in nine of 39 such patients. 
A curve of probability of remaining free of PLE 
for those who had renal failure (Fig. 3) demon- 
strates that PLE often developed early in the 
postoperative course and the rate may level off 
after 5 postoperative y ars. 
Multivariate analysis howed that the most favor- 
able outcome (lowest risk for development of PLE) 
occurs in patients with a dominant left ventricle, 
short hospital stay (less than 15 days), and no 
postoperative r nal failure. PLE has developed in 11 
of 154 patients (7%) in this group thus far. The 
probability curve for surviving free of PLE for this 
group also demonstrates the more favorable out- 
come (Fig. 4). 
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Table II. Univariate and multivariate assessment offactors associated with development ofPLE among 427 
30-day survivors of the Fontan operation* 
Cumulative risk of PLE (%) 
Factor No. Time 0 6 mo 1 yr 5 yr 10 yr Pu Pc Pm 
Overall group 427 0.0 0.5 1.0 8.7 13.4 - -  - -  - -  
Preoperative factors 
Basic anatomy 0.020 (5.4) - -  NS 
TA 148 0.0 0.7 0.7 3.7 8.0 
Univentricular complex 279 0.0 0.4 1.2 11.5 16.4 
Ventricular anatomy 0.010 (6.7) - -  0.021 
LV 306 0.0 0.3 0.3 6.1 10.4 
All others 103 0.0 1.0 2.1 17.1 20.3 
Age at Fontan (yr) NS NS NS 
<4 38 0.0 0.0 0.0 9.4 9.4 
>-4 389 0.0 0.5 1.1 8.6 13.7 
Preoperative arrhythmia NS - -  NS 
Absent 395 0.0 0.5 1.1 8.7 13.7 
Present 32 0.0 0.0 0.0 8.7 8.7 
LV ejection fraction (%) NS NS - -  
Normal (>50) 138 0.0 0.0 0.0 8.2 10.2 
Abnormal (<50) 52 0.0 2.1 4.3 10.1 15.0 
Mean PA pressure (ram Hg) NS NS - -  
Normal (<30) 330 0.0 0.6 1.0 9.5 14.4 
Abnormal (->30) 34 0.0 0.0 0.0 3.8 8.2 
Pulmonary arteriolar esistance (/xm z) NS NS - -  
Normal (-<3) 211 0.0 0.5 1.0 9.3 15.9 
Abnormal (>3) 14 0.0 0.0 0.0 16.7 16.7 
Total pulmonary resistance (/xm 2) NS 0.017 (5.7) - -  
Normal (<4) 160 0.0 0.0 0.7 7.7 11.7 
Abnormal (->4) 101 0.0 1.0 1.0 13.2 20.7 
LV end-diastolic pressure (mm Hg) 0.034 (4.5) 0.014 (6.0) - -  
Normal (<13) 225 0.0 0.9 1.4 7.4 9.2 
Abnormal (>13) 157 0.0 0.0 0.7 11.4 18.5 
Perioperative factors 
AV surgery NS - -  NS 
No 404 0.0 0.5 1.0 8.5 13.3 
Yes 23 0.0 0.0 0.0 13.8 13.8 
Postoperative arrhythmia NS - -  - -  
Absent 270 0.0 0.4 0.8 5.7 11.0 
Present 157 0.0 0.7 1.4 13.9 17.8 
Mean RAP after Fontan (mm Hg) NS NS - -  
Normal (<20) 290 0.0 0.4 1.1 6.8 11.8 
Abnormal (->20) 132 0.0 0.8 0.8 11.8 15.8 
Mean LAP after Fontan (mm Hg) <0.001 (12.8) <0.001 (13.0) - -  
Normal (<12) 262 0.0 0.4 0.8 5.4 8.6 
Abnormal (>-12) 137 0.0 0.8 1.6 14.1 23.2 
Early reoperation 0.020 (5.4) - -  NS 
No 353 0.0 0.6 1.2 7.5 11.7 
Yes 69 0.0 0.0 0.0 15.7 25.1 
Bypass time (min) 0.011 (6.5) 0.044 (4.1) NS 
-----120 221 0.0 0.0 0.5 5.5 8.7 
>120 206 0.0 1.0 1.6 12.3 19.0 
AV,, Atrioventricular valve; LAP, left atrial pressure; LV, left ventricle; PA, pulmonary artery; RAP, right atrial pressure; TA, tricuspid atresia. Pu refers to 
univariate probability value from log-rank test with nonsignificance (NS) ifPu > 0.05. With each significant finding, the associate X 2 statistic isin parentheses. 
Pc refers to univariate probability value from Cox regression model testing the association between the risk of the development ofPLE and the predictor 
variable treated as a continuous variable. Pm refers to a two-tailed p value considering the variable in a multivariate context using both preoperative and 
postoperative ariables. Those significant were identified by a stepwise backwvard elimination of the nonsignificant (NS) variables. Those variables not 
considered are indicated by a dash line (--). 
*The end point considered in these analyses was the development ofPLE. Death in patients who did not have PLE was treated as a censored observation 
for all these anslyses. 
tNumber of days hospitalized of the first 30 postoperative days. Hospital stays beyond 30 days were treated as 30 days for this analysis. 
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Table II. Cont'd. 
Cumulative risk of PLE (%) 
Factor No. Time 0 6 mo 1 yr 5 yr 10 yr Pu Pc Pm 
Postoperative r nal failure 
Yes 39 0.0 3.0 6.4 27.7 33.7 
No 388 0.0 0.3 0.5 7.1 11.6 
Hospital stayt (days) 
~<14 190 0.0 0.0 0.0 2.2 7.4 
15+ 237 0.0 0.9 1.9 14.7 18.9 
-<15 206 0.0 0.0 0.0 2.5 7.3 
16-29 157 0.0 0.7 2.0 14.2 17.5 
30 64 0.0 1.9 1.9 20.0 29.3 
<0.001 (14.1) 
<0.001 (11.9) 
<0.001 (18.7) 
0.025 
<0.001 (16.7) <0.001 
Discussion 
This report is the largest and most comprehensive 
study of PLE cases after the Fontan operation. The 
chance of PLE developing among 30-day survivors 
was approximately 13.4% by 10 years. Other reports 
in the literature have been limited by the small 
number of patients or the brevity of the follow- 
up.4. 5 The data reported in this article show that 
PLE can be a late complication; therefore continued 
and careful follow-up of all patients who have had 
the Fontan operation is considered necessary to 
identify those in whom PLE may develop in the late 
follow-up period. 
Diagnosis and clinical manifestations of PLE. 
The diagnosis of PLE is reasonably certain for these 
patients. Data in the literature 13-15 suggest that 
al-antitrypsin studies accurately detect excessive 
loss of enteric protein and, therefore, this test 
remains the standard for documenting PLE. In this 
retrospective r view involving patients operated on 
between 1973 and 1987, al-antitrypsin data were not 
available for all patients. With reasonable certainty, 
a retrospective r view could identify patients who fit 
the clinical syndrome of PLE. Two points are worth 
emphasizing. Most frequently, the onset of PLE is 
heralded by a new onset of pleural effusion, ascites, 
or peripheral edema. In the presence of hypopro- 
teinemia and no other cause for protein loss, the 
diagnosis of PLE is reasonable. Changes in gastro- 
intestinal signs and symptoms are relatively uncom- 
mon. This is in contrast to other diseases associated 
with PLE resulting from primary gastrointestinal 
disease.ll, 16-18 The effect of protein loss on matura- 
tion has been documented in patients whose growth 
has been delayed as well as in one instance of delay 
in the onset of puberty. Similar problems have been 
identified for noncardiac auses of PLE. 18 
PLE is represented by a spectrum of severity, with 
a patient mortality rate of 54% by 5 years after the 
diagnosis. The mortality rate noted for patients with 
PLE has not been reported previously. The survival 
data for all 30-day survivors is similar to findings 
reported by Fontan and associates 19in 1990. 
The fact that PLE can be transient suggests that 
other phenomena may have an effect, such as an 
intercurrent bacterial intestinal infection that oc- 
curred in one patient. The adverse ffect of living at 
high altitude after a Fontan operation is suggested 
by the finding that the condition of one patient 
improved after he moved from high altitude to sea 
level. The improvement in the condition of one 
patient coincident with the use of atrioventricular 
sequential pacing is of interest, but this modality is 
still untested. PLE has developed in patients who 
had pacemakers placed at the time of their Fontan 
operation. 
The laboratory manifestations of PLE (hypopro- 
teinemia, hypoalbuminemia, hypocalcemia, and 
lymphocytopenia) have been observed in other 
forms of PLE. Despite low levels of lymphocytes, a 
severe infection or a septic catastrophe did not 
develop in any of these patients. Although periodic 
albumin infusions have been used, gamma globulin 
infusions have not been considered necessary. 
Management. The fact that anticongestive mea- 
sures are not curative should not discourage the 
physician from vigorously initiating this therapy. A 
tendency toward improvement in the amount of 
enteric protein loss has been associated with the 
diuresis that comes with reinstituting digoxin, furo- 
semide, and afterload-reduction agents. Unfortu- 
nately, there is usually still excessive nteric protein 
loss despite initiation of therapy. A clinical manage- 
ment strategy of periodic albumin infusions with 
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Fig. 3. Curve of probability of remaining free of PLE for the 39 patients who had renal failure after their 
Fontan operation. Numbers in parentheses are survivors free of PLE at 5 and 10 years. Time zero is 30 days 
after the Fontan operation. 
intravenous administration f furosemide has been 
judged clinically effective for some patients and, in 
those who have stable ventricular function and other 
hemodynamic factors, has been used for extended 
periods without negative sequelae. The long-term 
use of dietary changes other than sodium restriction 
has not been successful for this group of patients. 
Part of management should include frequent fol- 
low-up visits with serial measures of serum proteins 
and al-antitrypsin stool concentrations. Serial echo- 
cardiographic studies to monitor ventricular func- 
tion have also been done. 
Hemodynamie findings for patients with PLE. 
The hemodynamie findings in patients who had 
cardiac atheterization coincident with development 
of PLE demonstrate increased right-sided pressures, 
decreased cardiac output, decreased ventricular sys- 
tolic function, and abnormal ventricular diastolic 
function as measured by end-diastolic pressure or 
mean wedge pressures. Comparisons between he- 
modynamic findings for this group of patients and 
for other patients who are 30-day survivors without 
PLE would be distorted by the fact that the only 
patients having catheterization were those in whom 
hemodynamic derangement was suspected. Further- 
more, these patients represented a clinical spectrum 
of severity, and protocols uch as fluid challenge 
were not used during this period. 
These data do describe the hemodynamic abnor- 
malities een for the first time in patients with PLE, 
however. The relative importance of one hemody- 
namic variable and PLE could not be identified. 
The experience at the Mayo Clinic with use of 
corticosteroids in patients with PLE has not been 
favorable. Barber (Barber G, New York University 
Medical Center, personal communication) has 
noted a subgroup of patients with PLE after the 
Fontan operation who, at cardiac catheterization, 
have relatively normal right-sided pressures. He 
believes that these patients hould have an intestinal 
biopsy and, if a cellular infiltrate is noted on biopsy, 
may respond favorably to corticosteroid therapy. In 
the patients in the present study, low right-sided 
pressures were infrequent and none had received 
corticosteroid therapy. 
Although cardiac transplantation has been used 
infrequently in the past, it is the option that may be 
considered for patients who have PLE associated 
with deteriorating hemodynamic variables and poor 
response to anticongestive measures. If transplanta- 
tion is considered, it should be undertaken before 
nutritional debilitation is manifest. The role of 
creating a right-to-left shunt at the atrial level as a 
method of treating PLE has been used on too few 
patients to reach a conclusion about this strategy. 
However, arecent report has suggested benefit from 
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Fig. 4. Curve of probability of remaining free of PLE for the 154 patients with a dominant left ventricle 
whose hospital stay was less than 15 days and who did not have renal failure after the Fontan operation. 
Numbers in parentheses are survivors free of PLE at 5 and 10 years. Time zero is 30 days after the Fontan 
operation. 
that approach. 2°Theoretically, lowering right atrial 
pressure might result in clinical improvement of 
PLE provided that other measures of cardiac func- 
tion are adequate and stable. 
Factors associated with development of PLE. 
The finding of significant preoperative and periop- 
erative factors associated with later development of
PLE resulted from statistical methods imilar to the 
one reported by Driscoll and associates. 1° This 
series looked only at 30-day survivors and included a
longer operative xperience. Similarities in mortal- 
ity risk noted by Driscoll's group 1° and results in this 
report are not surprising. Unfavorable preoperative 
factors included defect other than tricuspid atresia, 
ventricular anatomy other than dominant left ven- 
tricle, increased ventricular end-diastolic pressure, 
and increased total pulmonary resistance. These 
findings clearly emphasize the need to be scrupulous 
in selecting patients for the Fontan operation. Un- 
favorable perioperative factors included prolonged 
duration of cardiopulmonary b pass, increased post- 
operative left atrial pressure, postoperative renal 
failure, and increased uration of postoperative hos- 
pital stay. It was not possible to analyze other potential 
postoperative risk factors for PLE, such as duration of 
pleural effusions, because of the aggressive and highly 
effective use of chemical and mechanical pleurodesis 
during this period. The presence of one or more of 
those unfavorable variables hould help alert the clini- 
cian to the possible increased risk of PLE occurring 
later in the patient's postoperative course. 
This retrospective r view includes patients oper- 
ated on with techniques for the Fontan operation 
used before February 1, 1987. Since that time direct 
cava-pulmonary artery connections, lateral atrial 
tunnel, and similar techniques have been intro- 
duced. Short-term mortality rates after the Fontan 
operation have declined steadily since 1987. 21 This 
improvement may well result from a combination of 
better case selection and improved surgical tech- 
niques. It remains to be seen whether experience 
since 1987 is associated with a lower rate for PLE 
development during the postoperative course. Be- 
cause PLE may be a late complication, follow-up of 
at least 5 years is needed to assess the effects of 
newer operative techniques on' incidence of this 
complication. 
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